Share:
Pfizer announced that it is seeking FDA Emergency Use Authorization for its investigational COVID-19 oral antiviral candidate, and that it signed a voluntary license agreement for its treatment candidate with the Medicines Patent Pool:
- Pfizer seeks Emergency Use Authorization for novel COVID-19 oral antiviral candidate
- Pfizer and the Medicines Patent Pool sign licensing agreement for COVID-19 oral antiviral treatment candidate to expand access in low- and middle-income countries
SEE ALSO:
- MSF response to license between Pfizer and Medicines Patent Pool for new COVID-19 treatment Paxlovid
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.